Jim Simons
SGMT icon

Jim Simons’s Sagimet Biosciences SGMT Stock Holding History

Jim Simons’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Sell
346,927
-278,542
-45% -$1.89M ﹤0.01% 1808
2026
Q1 		$3.27M Buy
625,469
+282,969
+83% +$1.58M 0.01% 1616
2025
Q4 		$2.03M Buy
342,500
+181,100
+112% +$1.3M ﹤0.01% 1858
2025
Q3 		$1.11M Buy
161,400
+130,500
+422% +$1.06M ﹤0.01% 2428
2025
Q2 		$235K Buy
+30,900
New +$130K ﹤0.01% 3125
2025
Q1 		– Sell
-10,800
Closed -$48.6K – 3798
2024
Q4 		$48.6K Sell
10,800
-220,300
-95% -$1.12M ﹤0.01% 3395
2024
Q3 		$640K Sell
231,100
-11,300
-5% -$34.8K ﹤0.01% 2671
2024
Q2 		$829K Sell
242,400
-177,000
-42% -$812K ﹤0.01% 2426
2024
Q1 		$2.27M Buy
419,400
+396,400
+1,723% +$2.85M ﹤0.01% 1948
2023
Q4 		$125K Buy
+23,000
New +$109K ﹤0.01% 3249

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jim Simons's SGMT Position: Q2 2026 in Review

Jim Simons reduced its Sagimet Biosciences (SGMT) stake by 45% in Q2 2026, selling an estimated $1.89M and leaving 346,927 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

Jim Simons first reported a position in SGMT in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.27M in Q1 2026. 69 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Jim Simons held 346,927 shares of Sagimet Biosciences worth $2.68M as of Q2 2026.
  • Jim Simons sold 278,542 Sagimet Biosciences shares in Q2 2026, an estimated $1.89M.
  • Sagimet Biosciences made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #1808 holding.
  • Jim Simons first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Jim Simons's Sagimet Biosciences position peaked at $3.27M in Q1 2026.
  • 69 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.